Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
Stefan D. Anker(German Centre for Cardiovascular Research), Milton Packer(Baylor Jack and Jane Hamilton Heart and Vascular Hospital), Michael Böhm(Saarland University), Martina Brueckmann, Piotr Ponikowski(Wroclaw Medical University), Nikolaus Marx(University of Cologne), Javed Butler(University of Mississippi Medical Center), Gerasimos Filippatos(National and Kapodistrian University of Athens), Stuart Pocock(University of London), Sergio V. Perrone(Inserm), Sven Schnaidt(Inserm), Anne Pernille Ofstad(Boehringer Ingelheim (Norway)), Faı̈ez Zannad(Inserm), James L. Januzzi(Harvard University), Muhammad Shahzeb Khan(University of Mississippi Medical Center), Carolyn S.P. Lam, Subodh Verma(University of Toronto), João Pedro Ferreira(Inserm), E A Bocchi(Universidade de São Paulo), Waheed Jamal(Inserm)
Cited by 350
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k